Načítá se...
Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients
Optimal care for breast cancer patients undergoing aromatase inhibitor (AI) treatment is ensured when estradiol (E(2)) levels are adequately suppressed. To assess treatment efficacy accurately, it is important to measure the serum E(2) levels using a well validated assay method with high sensitivity...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3599208/ https://ncbi.nlm.nih.gov/pubmed/23520572 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2193-1801-2-5 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|